Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a. Additionally we are shipping C5AR1 Kits (12) and C5AR1 Proteins (7) and many more products for this protein.
Showing 10 out of 274 products:
Human Monoclonal C5AR1 Primary Antibody for FACS - ABIN951419
Kiafard, Tschernig, Schweyer, Bley, Neumann, Zwirner: Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in tubular epithelial cells of human, murine and rat kidneys. in Immunobiology 2007
Show all 6 references for 951419
Human Polyclonal C5AR1 Primary Antibody for EIA, FACS - ABIN951423
Skeie, Fingert, Russell, Stone, Mullins: Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. in Investigative ophthalmology & visual science 2010
Show all 5 references for 951423
Human Monoclonal C5AR1 Primary Antibody for FACS, IHC (fro) - ABIN181855
Oppermann, Raedt, Hebell, Schmidt, Zimmermann, Götze: Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain. in Journal of immunology (Baltimore, Md. : 1950) 1993
Show all 3 references for 181855
Human Polyclonal C5AR1 Primary Antibody for IHC, ELISA - ABIN1531549
Gerard, Gerard: The chemotactic receptor for human C5a anaphylatoxin. in Nature 1991
Show all 3 references for 1531549
Rat (Rattus) Monoclonal C5AR1 Primary Antibody for FACS - ABIN120012
Rothermel, Götze, Zahn, Schlaf: Analysis of the tissue distribution of the rat C5a receptor and inhibition of C5a-mediated effects through the use of two MoAbs. in Scandinavian journal of immunology 2000
Show all 2 references for 120012
Cow (Bovine) Monoclonal C5AR1 Primary Antibody for FACS, IHC (p) - ABIN118843
Werfel, Zwirner, Oppermann, Sieber, Begemann, Drommer, Kapp, Götze: CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin. in Journal of immunology (Baltimore, Md. : 1950) 1996
Show all 2 references for 118843
Human Polyclonal C5AR1 Primary Antibody for FACS, WB - ABIN654658
Marc, Kristan, Rozman, Kern, Flezar, Kosnik, Korosec: Complement factor C5a in acute exacerbation of Chronic Obstructive Pulmonary Disease. in Scandinavian journal of immunology 2010
Show all 2 references for 654658
Human Monoclonal C5AR1 Primary Antibody for FACS - ABIN4895404
Pundir, MacDonald, Kulka: The Novel Receptor C5aR2 Is Required for C5a-Mediated Human Mast Cell Adhesion, Migration, and Proinflammatory Mediator Production. in Journal of immunology (Baltimore, Md. : 1950) 2015
Human Monoclonal C5AR1 Primary Antibody for FACS - ABIN4895403
Reis, Chen, Sfyroera, Monk, Köhl, Ricklin, Lambris: C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay. in Journal of immunology (Baltimore, Md. : 1950) 2012
Data indicate that complement component 5a receptor 1 protein (C5aR1) signaling in osteoblasts plays a detrimental role in bone regeneration after fracture.
The role of C5aR1 and C5aR2 in response to renal ischemia-reperfusion injury is reported. The results also demonstrated that C5aR2 is a functional receptor, rather than a decoy receptor, and may provide a new target for intervention.
these data reveal a differential role for C5aR during ethanol-induced liver inflammation and injury
These findings demonstrate a complex regulation pattern of C5aR1 in the airways, lung tissue and mediastinal lymph nodes of mice, suggesting that the C5a/C5aR1 axis controls airway constriction and inflammation through activation of myeloid cells in all three compartments in an experimental model of allergic asthma.
C5aR1-KO mice exhibited less renal injury, as evidenced by reduced albuminuria. In contrast, cardiac injury was accelerated with increased cardiac fibrosis and heart weight in C5aR1-deficient mice after ANG II (show AGT Antibodies) infusion. No effect was found on blood pressure. the C5a:C5aR1 axis drives end-organ damage in the kidney but protects from the development of cardiac fibrosis and hypertrophy in experimental hypertension.
This study demonstrated that C5aR1 contributes to the acute inflammatory response elicited by infiltrating immune cells following pilocarpine status epilepticus.
Regulation of complement 5a receptor (C5aR)-induced neutrophil chemotaxis via IgG1 immune complexes (ICs (show DNAI1 Antibodies)) depends on galectin-3 (show LGALS3 Antibodies).
The C5a/C5aR pathway is essential for up-regulating SphK1 (show SPHK1 Antibodies) expression through p38 MAPK (show MAPK14 Antibodies) activation in acute liver failure.in mice.
C5a bidirectionally amplifies TLR4 (show TLR4 Antibodies)-mediated NLRP3 (show NLRP3 Antibodies) inflammasome activation in monocytes while suppressing this pathway in macrophages. However, as C5aR1 deficiency attenuates the IL-1beta (show IL1B Antibodies) response to LPS (show TLR4 Antibodies) challenge in vivo, results suggest overall that C5a augments physiologic inflammasome responses.
CYP4F18 (show CYP4F3 Antibodies)-deficient neutrophils exhibit increased chemotaxis to complement component C5a.
TLR4 (show TLR4 Antibodies) and C5aR crosstalk in dendritic cells induces a core regulatory network of RSK2 (show RPS6KA3 Antibodies), PI3Kbeta, SGK1 (show SGK1 Antibodies), and FOXO (show FOXO3 Antibodies) transcription factors.
Results showed that 7-oxygenated cholesterol derivatives have differential effects on monocyte/macrophage expression of IL-8 (show IL8 Antibodies) and C5a receptor and that C5a receptor is involved in 7alphaOHChol-induced IL-8 (show IL8 Antibodies) expression via PI3K (show PIK3CA Antibodies) and MEK (show MAP2K1 Antibodies). Study demonstrated expression of IL-8 (show IL8 Antibodies) and C5a receptor primarily by 7alpha-hydroxycholesterol in monocytes/macrophages.
Reducing RPS19 (show RPS19 Antibodies) in tumor cells or blocking the C5a receptor 1-RPS19 (show RPS19 Antibodies) interaction decreases RPS19 (show RPS19 Antibodies)-mediated immunosuppression, impairs tumor growth, and delays the development of tumors in a transgenic model of breast cancer
C5aR expression in gastric cancer was associated with cancer progression, liver metastasis, and poor prognosis.
this study shows that downregulation of CD88 after stimulation with IL-8 (show IL8 Antibodies) is more pronounced in adults than in neonates, whereas fMLP (show FPR1 Antibodies) induces changes in receptor expression that are of the same magnitude in neutrophils from neonates as from adults
Relation of C5aR expression to tumor development and poor prognosis of the breast cancer patients
The objective of the present study was to validate a receptor occupancy (RO) assay for a human anti-C5aR monoclonal antibody drug candidate, NNC0215-0384 (NN0384)
These data thus suggest that C5aR1 acts as an enhancer of CCR5-mediated HIV entry into macrophages, the targeting of which may prove useful to reduce HIV infection by R5 strains.
C5AR and C5L2 (show GPR77 Antibodies)-mediated neutrophil dysfunction is associated with a poor outcome in sepsis.
that C5aR stimulates cell invasion and migration via ERK1/2 (show MAPK1/3 Antibodies)-mediated epithelial-mesenchymal transition in hepatocellular carcinoma cells
Studies provide information regarding distinct structural and functional features that may contribute to the unique pharmacological properties of bovine C5aR.
Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a. This receptor stimulates chemotaxis, granule enzyme release and superoxide anion production.
complement component 5a receptor 1
, C5a anaphylatoxin receptor
, G protein-coupled receptor 77
, C5a anaphylatoxin chemotactic receptor 1
, C5a ligand
, complement component 5, receptor 1
, complement component 5 receptor 1
, complement C5a receptor
, anaphylatoxin C5a receptor
, complement component 5 receptor 1 (C5a ligand)
, C5a anaphylatoxin chemotactic receptor